Algorae Pharmaceuticals
Algorae Pharmaceuticals (ASX: 1AI) is an Australian pharmaceutical company combining AlgoraeRx, a Source-Register-Supply generic and specialty medicines business serving Australian and New Zealand hospitals, with AlgoraeOS, an AI drug-discovery platform validated at Peter MacCallum Cancer Centre, licensing AI-discovered drug combination candidates to pharma partners.
- Company typePublic
- Founded1987
- HeadquartersManukau City, New Zealand
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Algorae Pharmaceuticals does
Algorae Pharmaceuticals Ltd (ASX: 1AI) is an Australian-headquartered pharmaceutical company operating a dual-track strategy that pairs a commercial generic and specialty medicines supply business with an AI-powered drug discovery platform. The company is publicly listed on the Australian Securities Exchange, headquartered in Melbourne, and reports operations across Australia and New Zealand.
The commercial division, AlgoraeRx, runs a Source-Register-Supply model that identifies generic and specialty medicines addressing unmet medical needs, secures license and supply agreements with Tier-1 global manufacturers (GMP-certified suppliers already serving the US, EU and other regulated markets), obtains TGA regulatory approvals, and supplies products to institutional hospital and healthcare buyers across Australia and New Zealand. The company indicates three executed supply agreements, a non-dilutive $3M receivables facility, and an eight-product pipeline, with Dr Reddy's Laboratories signed as distribution partner for capecitabine (announced November 2025) and Sakar Healthcare licensing five generic oncology medicines (combined ANZ market estimated at ~$10M per annum). Headcount is 1–10, and revenue is not publicly disclosed.
The R&D division, AlgoraeOS, is an AI drug discovery platform developed in collaboration with UNSW AI Institute (uDASH) and CSIRO Data61, with independent wet-lab validation conducted at the Peter MacCallum Cancer Centre. The platform is trained on 5.5M+ inhibition records spanning 3,000+ drugs and 170 cancer cell lines; the v2 release (AOS2) reportedly outperformed Google DeepMind models in published benchmarks across Bliss, Loewe, HSA and ZIP synergy formalisms. AlgoraeOS generates high-confidence drug-combination candidates available for licensing and co-development, with two priority candidates—AI-116 (CBD + donepezil for dementia, PCT/AU2024/050791, developed with La Trobe University) and AI-168 (cannabinoid combination for cardiovascular disease, PCT/AU2024/051253, developed with Monash Biomedicine Discovery Institute / Victorian Heart Institute)—alongside the legacy NTCELL encapsulated choroid plexus cell therapy for Parkinson's disease, protected by the registered IMMUPEL alginate coating IP. The platform IP is 100% owned by Algorae, and each validation cycle feeds a closed-loop flywheel intended to compound the platform's predictive capability.
Algorae Pharmaceuticals firmographics
Firmographics- Name
- Algorae Pharmaceuticals
- Legal name
- Algorae Pharmaceuticals Ltd
- Website
- https://algoraepharma.com
- Company type
- Public
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Algorae Pharmaceuticals (ASX: 1AI) is an Australian pharmaceutical company combining AlgoraeRx, a Source-Register-Supply generic and specialty medicines business serving Australian and New Zealand hospitals, with AlgoraeOS, an AI drug-discovery platform validated at Peter MacCallum Cancer Centre, licensing AI-discovered drug combination candidates to pharma partners.
- Ownership category
- akta.pro rank
Algorae Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceuticals Supply
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)
- akta.pro secondary industries
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Algorae Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Manukau City
- HQ country
- New Zealand
- HQ region
- Oceania
Offices1 record
Markets served
Algorae Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Generic and Specialty Medicines Supply: AlgoraeRx sources generic and specialty medicines from leading global manufacturers, secures TGA regulatory approvals, and supplies them to the Australian institutional market through executed supply and licensing agreements with Tier-1 global manufacturers. Products are sourced exclusively from GMP-certified manufacturers already supplying the US, EU and other highly regulated markets.
- Licensing and Co-development Deals: AlgoraeOS generates high-confidence drug-combination candidates available for out-licensing to pharmaceutical partners and co-development arrangements. AI-116 (PCT/AU2024/050791) and AI-168 (PCT/AU2024/051253) are priority licensing candidates.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Algorae Pharmaceuticals product offering
Product offeringCore offering
Algorae Pharmaceuticals operates two divisions: AlgoraeRx, which sources generic and specialty medicines from Tier-1 global manufacturers, secures TGA regulatory approvals, and supplies them to Australian and New Zealand institutional markets through a Source-Register-Supply model; and AlgoraeOS, an AI-powered drug discovery platform developed with UNSW and CSIRO Data61 that generates novel drug-combination candidates for licensing and co-development across oncology, dementia, cardiovascular disease, and Parkinson's.
Product overview
Algorae Pharmaceuticals operates a dual-track strategy comprising two main product lines: AlgoraeRx (commercial pharmaceutical division) and AlgoraeOS (AI-powered drug discovery platform). AlgoraeRx sources and supplies generic and specialty medicines through a Source-Register-Supply model with Tier-1 global manufacturers. AlgoraeOS is an AI platform that generates drug-combination candidates, with specific programs including AI-116 (CBD + donepezil for dementia), AI-168 (cannabinoid combination for cardiovascular disease), and NTCELL (cell therapy for Parkinson's disease).
Differentiator
Problem solved
Functional benefit
Brands
- AlgoraeRx: Commercial pharmaceutical division sourcing and supplying generic and specialty medicines to the Australian and New Zealand markets
- AlgoraeOS
Products and services
- AlgoraeRx Commercial pharmaceutical division that sources and supplies generic and specialty medicines to the Australian and New Zealand markets through a Source-Register-Supply model, with executed supply and licensing agreements with Tier-1 global manufacturers and TGA regulatory approvals.
- AlgoraeOS AI-powered drug discovery platform developed in partnership with UNSW AI Institute and CSIRO Data61, independently validated at Peter MacCallum Cancer Centre. Generates high-confidence novel drug-combination candidates across complex disease areas for licensing and co-development. Platform IP is 100% owned by Algorae.
- AI-116 Fixed-dose combination drug candidate comprising CBD and donepezil for dementia including Alzheimer's disease. Identified and validated by AlgoraeOS, demonstrating 53% cell viability vs 17% with donepezil alone in preclinical validation.
- AI-168 Fixed-dose combination drug candidate comprising a cannabinoid and off-patent pharmaceutical ingredient for cardiovascular disease including hypertension. Preclinical data shows 94% endothelial restoration, 80% smooth muscle normalisation, 68% reduction in cardiomyocyte damage.
- NTCELL Alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells for Parkinson's disease treatment. Uses proprietary IMMUPEL technology to protect cells from immune system attack without requiring immunosuppression. Developed from designated pathogen-free pig herd from Auckland Islands, New Zealand.
Quantifiable outcome
- 53% cell viability with AI-116 vs 17% with donepezil alone in preclinical validation
- +2 more outcomes
Companies that use Algorae Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Algorae Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Algorae Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Peter MacCallum Cancer CentrecoreSecond AI-driven drug synergy screening program testing twenty-four drug pairs across four cancer types. Peter MacCallum Cancer Centre provides independent wet-lab validation of AlgoraeOS platform predictions, including the Victorian Centre for Functional Genomics.
- UNSW AI Institute (uDASH)coreCollaboration with UNSW Data Science Hub (uDASH) for AlgoraeOS platform development. Professor Fatemeh Vafaee leads the AI Biomedical Laboratory as Principal Investigator, providing advanced AI tools, high-performance computing infrastructure, and machine learning expertise.
- CSIRO Data61coreCollaboration with CSIRO Data61 for AlgoraeOS v2 platform development. Data61 contributes data science expertise and computational resources to enhance the AI-powered drug discovery platform.
- La Trobe UniversitycoreAI-116 dementia program in co-development with La Trobe University. Professor Garrie Arumugam leads the program focusing on neuronal cell death mechanisms in stroke and vascular dementia.
- Monash Biomedicine Discovery Institute / Victorian Heart InstitutecoreAI-168 cardiovascular program in co-development. Dr Kristen Bubb leads the Translational Vascular Therapeutics Group with preclinical studies demonstrating 94% endothelial restoration, 80% smooth muscle normalisation, and 68% reduction in cardiomyocyte damage.
- Dr Reddy's LaboratoriescoreDistribution partnership for supply of chemotherapy drug capecitabine to Australian market. First shipment expected within one month of announcement. Complements ongoing validation trial at Peter MacCallum Cancer Centre.
- Sakar HealthcareminorLicensing agreement with Indian manufacturer to launch five generic oncology medicines in Australia and New Zealand. Combined market valued at approximately $10 million per annum.
- Tier-1 Global ManufacturerscoreSupply agreements with globally credentialled Tier-1 pharmaceutical manufacturers already supplying the US, EU and other highly regulated markets. Three supply agreements executed for generic and specialty medicines.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Algorae Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Exscientia: AI-driven drug discovery company with comparable platform-to-pharma licensing model and drug-combination/synergy prediction focus similar to AlgoraeOS.
- Schrödinger: Computational/AI platform for drug discovery that monetises through pharma partnerships and licensing, with published benchmarks against which AlgoraeOS AOS2 directly competes (Algorae claims to outperform Schrödinger-class models).
- Recursion Pharmaceuticals: AI-first drug discovery platform generating multi-program pipelines aimed at large pharma licensing; comparable in using predictive biological models and wet-lab validation loops to derisk candidates.
- Mayne Pharma: ASX-listed Australian pharma company operating in generic and specialty pharmaceutical supply, with comparable TGA-registered institutional focus and pipeline of niche medicines serving hospitals and specialty channels.
Broad incumbents
- EBOS Group: Australia and NZ's largest healthcare distribution business, including hospital and specialty pharmaceutical supply via its HPS division (where Algorae's COO previously led); the dominant incumbent that AlgoraeRx positions against in institutional supply.
- Sandoz: One of the world's largest generic pharmaceutical companies with significant Australian institutional and hospital footprint (Algorae's Head of Sales held Sandoz ANZ hospital leadership); the major multinational incumbent whose behaviour creates the supply shortage problem AlgoraeRx targets.
Emerging players
- BenevolentAI: AI drug discovery company with similar combination-repurposing and platform-licensing approach; useful comparable for the AI drug discovery and partner-funded pre-clinical development path Algorae is pursuing.
- Isomorphic Labs: Alphabet-backed AI drug discovery venture focused on platform deals with major pharma; sets the benchmark for what strategic acquirers pay for AI drug discovery IP and licences.
Regional players
- Sigma Healthcare: ASX-listed wholesale and retail pharmaceutical distributor serving Australian community and hospital pharmacies; comparable as a regional pharma-distribution incumbent where AlgoraeRx sells into the same institutional channels.
- Arrovest Pharmaceuticals (IDT Australia): Small ASX-listed Australian pharmaceutical manufacturer and specialty supplier of generic and niche medicines — comparable in scale and TGA-registered supply focus for institutional and hospital channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Algorae Pharmaceuticals social profiles
Digital presenceAlgorae Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Algorae Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles11 records
Algorae Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Algorae Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Algorae Pharmaceuticals
What does Algorae Pharmaceuticals do?
Algorae Pharmaceuticals operates two divisions: AlgoraeRx, which sources generic and specialty medicines from Tier-1 global manufacturers, secures TGA regulatory approvals, and supplies them to Australian and New Zealand institutional markets through a Source-Register-Supply model; and AlgoraeOS, an AI-powered drug discovery platform developed with UNSW and CSIRO Data61 that generates novel drug-combination candidates for licensing and co-development across oncology, dementia, cardiovascular disease, and Parkinson's.
Is Algorae Pharmaceuticals a public or private company?
Algorae Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Algorae Pharmaceuticals founded?
Algorae Pharmaceuticals was founded in 1987. It employs 1 to 10 people.
Where is Algorae Pharmaceuticals based?
Algorae Pharmaceuticals is headquartered in Manukau City, New Zealand, in the Oceania region.
How does Algorae Pharmaceuticals make money?
Two revenue lines are on record. Generic and Specialty Medicines Supply is the primary driver. The others are licensing and Co-development Deals.
Who are Algorae Pharmaceuticals's main competitors?
Direct peers on record are Exscientia, Schrödinger, Recursion Pharmaceuticals and Mayne Pharma. Broad incumbents are EBOS Group and Sandoz. Emerging players are BenevolentAI and Isomorphic Labs. Regional players are Sigma Healthcare and Arrovest Pharmaceuticals (IDT Australia).
Does Algorae Pharmaceuticals have an API?
No public API is recorded for Algorae Pharmaceuticals.
What industry is Algorae Pharmaceuticals in?
Algorae Pharmaceuticals's product category is Generic Pharmaceuticals Supply. Its primary akta.pro industry code is HLAIAJAN, Controlled Substances & Compliance-Focused Pharmaceutical Distributors, with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 424210 and its SIC code is 5122.